Sigyn Therapeutics explores NASDAQ merger, establishes clinical pathway
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St rebounds with broad gains as oil slides sharply
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Sigyn Therapeutics Issues Shareholder Update Highlighting the Advancement of CardioDialysis(TM) and New Corporate Initiatives
January 15, 2026 11:01 AM ESTSAN DIEGO, CA - January 15, 2026 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. (Sigyn or the Company) (OTCQB: SIGY), a developer of dialysis-like therapies to address cardiovascular disease and cancer, today released the following shareholder update authored by Chief Executive Officer, Jim Joyce.
Dear Shareholders and Interested Parties,
Cardiovascular disease is the #1 cause of death worldwide. The primary aim of treatment is to reduce major adverse cardiovascular events (MACE).
The leading class of drugs to treat cardiovascular disease are statins, which reduce the incidence of MACE by approximately 25%. In contrast, blood purification therapies (lipoprotein apheresis) can... More
